QBiotics has announced positive results from its Phase II QB46C-H08 trial, with tigilanol tiglate achieving a 78% Objective Response Rate (ORR) in patients with head and neck solid malignancies who were refractory to standard of care. The company says the result, based on 14 responses across 18… Read More
A new resource is now available to download for free. MASLD drug development is limited by models that don’t reflect human liver biology. HUB’s patient-derived liver organoids retain donor genetics, architecture and physiology. Download the Factsheet to learn: How organoids recapitulate steatosis and fibrosis Which readouts support target validation… Read More
Six promising companies will receive additional funding of €1.3 ($1.5) million each from BioInnovation Institute (BII) to help them bring their technologies and products closer to market. The six companies – PanTarg, 3Sonic, Inia Biosciences, Yngvi Bio, Proxi Biotech and Sagava – have all previously received €0.5… Read More
The Association of the British Pharmaceutical Industry’s (ABPI’s) 2026 flagship Competitiveness Report finds the UK has begun to reverse years of decline. However, the Association cautions that sustained delivery of government commitments will now determine whether the recovery holds. Since September 2025, the global pharmaceutical… Read More
Gan & Lee Pharmaceuticals and Menarini have announced plans to collaborate on the registration and commercialisation of Gan & Lee’s glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide. The drug is under development for the treatment of adults with obesity or overweight, administered once every two weeks. … Read More
Transgene and NEC Corporation have reported sustained 100% three-year disease-free survival (DFS) in patients treated with TG4050 in the Phase I part of a randomised Phase I/II trial. TG4050 is the first individualised neoantigen therapeutic vaccine (INTV) based on the myvac platform. It is… Read More
The US Food and Drug Administration (FDA) has approved Ionis Pharmaceuticals’ Zanvastro (zilganersen) for the treatment of Alexander disease (AxD) in paediatric and adult patients. It is the first and only disease modifying treatment for AxD, an ultra-rare, progressive and often fatal neurological disorder that can affect… Read More
Novartis and Bristol Myers Squibb (BMS) have both paused clinical trials of CAR-T cell therapies for lupus and other autoimmune diseases due to concerning safety findings. Novartis has placed holds on trials of rapcabtagene autoleucel (rap-cel), stopping screening, randomisation, and treatment administration in trials in lupus, myasthenia… Read More
GSK has revealed that its mRNA seasonal influenza (flu) vaccine candidate has shown higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines. The Phase II data were presented at the OPTIONS XIII Conference for the Control of… Read More
Eli Lilly has announced plans to acquire Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases. Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions. The… Read More
The US Food and Drug Administration (FDA) has approved Lilly’s Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV) events (MACE) in adults with type 2 diabetes. The drug is already approved as an adjunct to diet… Read More
Roche has acquired exclusive global rights to develop, manufacture, and commercialise SIM0660, a trispecific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases. Under the terms of the agreement, developer Simcere Zaiming is eligible to receive up to $1.530 billion in total payments, including… Read More
Evotec and Plectonic Biotech have announced a research collaboration to explore a novel immunotherapy approach for solid tumours. The collaboration aims to address key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumours by combining Plectonic’s programmable LOGIBODY… Read More
Safety evidence announced at the ESC Congress 2026 by Isomab has reinforced the potential of a new class of therapies designed to promote blood vessel growth as a disease-modifying approach for coronary artery disease (CAD). The systematic review of clinical trial data evaluating growth factor approaches, spanning… Read More
Biohaven and SK Biopharmaceuticals have agreed a strategic global licensing and collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to Biohaven’s Kv7 ion channel platform. The platform is led by opakalim (BHV-7000), a next-generation, selective Kv7.2/7.3 potassium channel activator in Phase II/III development… Read More
The way cancer-causing proteins accumulate in tumours may influence how effectively Proteolysis Targeting Chimeras (PROTAC) drugs can remove them, a new study suggests. Researchers found that PROTACs were more effective at removing proteins that build up because they are not broken down properly than proteins that cancer… Read More
